FDA approves former Genmab drug - royalties to follow

The US health authority, the FDA, has approved Horizon Therapeutics' eye medicine teprotumumab, which may earn Genmab a significant amount in royalties.

Jan van de Winkel, CEO of Genmab, can look forward to another source of earnings for the company. Photo: Mik Eskestad / Jyllands-Posten / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles